Ratings by JPMorgan (Jessica Fye)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/20/2026 | Mirum Pharmaceuticals | MIRM | New Coverage | Overweight (N/A) |
95.49 (107.77) |
12.86% | Details | |
| 5/20/2026 | Halozyme Therapeutics | HALO | New Coverage | Neutral (N/A) |
67.44 (68.99) |
2.3% | Details | |
| 5/20/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Overweight (N/A) |
49.67 (55.90) |
12.54% | Details | |
| 5/20/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Overweight (N/A) |
72.52 (75.89) |
4.65% | Details | |
| 5/20/2026 | Jazz Pharmaceuticals | JAZZ | New Coverage | Overweight (N/A) |
229.55 (225.92) |
-1.58% | Details | |
| 5/20/2026 | Ascendis Pharma | ASND | New Coverage | Overweight (N/A) |
237.64 (228.00) |
-4.06% | Details | |
| 5/20/2026 | Incyte | INCY | New Coverage | Neutral (N/A) |
95.19 (103.66) |
8.9% | Details | |
| 5/20/2026 | Moderna | MRNA | New Coverage | Underweight (N/A) |
48.11 (59.35) |
23.36% | Details | |
| 5/20/2026 | BioNTech | BNTX | New Coverage | Neutral (N/A) |
88.85 (90.19) |
1.51% | Details | |
| 5/20/2026 | Insmed | INSM | New Coverage | Overweight (N/A) |
107.15 (98.61) |
-7.97% | Details | |
| 5/20/2026 | United Therapeutics Corp. | UTHR | New Coverage | Overweight (N/A) |
566.99 (538.30) |
-5.06% | Details | |
| 5/20/2026 | BeOne Medicines | ONC | New Coverage | Overweight (N/A) |
293.09 (271.80) |
-7.26% | Details | |
| 5/20/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Overweight (N/A) |
286.27 (286.41) |
0.05% | Details | |
| 5/20/2026 | Vertex | VRTX | New Coverage | Overweight (N/A) |
436.58 (466.79) |
6.92% | Details | |
| 2/3/2026 | Akoustis Technologies | AKTS | New Coverage | Overweight (N/A) |
20.25 (24.79) |
22.42% | Details | |
| 11/4/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/27/2025 | NovoCure Ltd. | NVCR | Maintain | Neutral (Neutral) |
|
Details | ||
| 10/27/2025 | Halozyme Therapeutics | HALO | Maintain | Neutral (Neutral) |
|
Details | ||
| 10/23/2025 | Moderna | MRNA | Maintain | Underweight (Underweight) |
|
Details | ||
| 10/23/2025 | BioNTech | BNTX | Maintain | Neutral (Neutral) |
|
Details | ||
| 10/9/2025 | Legend Biotech Corp. | LEGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/9/2025 | Incyte | INCY | Maintain | Neutral (Neutral) |
|
Details | ||
| 10/9/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/9/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/8/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/8/2025 | BeOne Medicines | ONC | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/8/2025 | Ionis Pharmaceuticals | IONS | Upgrade | Overweight (Neutral) |
69.02 (75.89) |
9.95% | Details | |
| 9/24/2025 | Crinetics | CRNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/22/2025 | BioNTech | BNTX | Maintain | Neutral (Neutral) |
|
Details | ||
| 9/9/2025 | United Therapeutics Corp. | UTHR | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/9/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/25/2025 | Legend Biotech Corp. | LEGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/25/2025 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/22/2025 | Incyte | INCY | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/20/2025 | United Therapeutics Corp. | UTHR | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/20/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/19/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/7/2025 | Halozyme Therapeutics | HALO | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/6/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/5/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/29/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/21/2025 | NovoCure Ltd. | NVCR | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/17/2025 | BeOne Medicines | ONC | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/16/2025 | Halozyme Therapeutics | HALO | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/14/2025 | Incyte | INCY | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/14/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/14/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/8/2025 | United Therapeutics Corp. | UTHR | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/8/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/12/2025 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/3/2025 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 6/2/2025 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/29/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/29/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2025 | Moderna | MRNA | Maintain | Underweight (Underweight) |
|
Details | ||
| 5/22/2025 | BioNTech | BNTX | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/15/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/6/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/6/2025 | BioCryst Pharma | BCRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/2/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/21/2025 | United Therapeutics Corp. | UTHR | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/21/2025 | Incyte | INCY | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/21/2025 | Halozyme Therapeutics | HALO | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/21/2025 | BeiGene Ltd. | ONC | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/14/2025 | Immunocore Holdings | IMCR | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/10/2025 | NovoCure Ltd. | NVCR | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/4/2025 | Mirum Pharamceuticals | MIRM | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/26/2025 | Crinetics | CRNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/24/2025 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/24/2025 | Alkermes | ALKS | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/24/2025 | Alnylam Pharmaceuticals | ALNY | Upgrade | Overweight (Neutral) |
253.54 (286.41) |
12.96% | Details | |
| 3/21/2025 | Moderna | MRNA | Maintain | Underweight (Underweight) |
|
Details | ||
| 3/18/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2025 | United Therapeutics Corp. | UTHR | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/11/2025 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/11/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/3/2025 | BeiGene Ltd. | ONC | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/24/2025 | BioCryst Pharma | BCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/12/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/12/2025 | Incyte | INCY | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/7/2025 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2025 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2025 | Incyte | Incy | Maintain | Neutral (N/A) |
|
Details | ||
| 1/29/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/27/2025 | Moderna | MRNA | Maintain | Underweight (N/A) |
|
Details | ||
| 1/27/2025 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/27/2025 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 1/7/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 12/23/2024 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/25/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2024 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2024 | Moderna | MRNA | Maintain | Underweight (N/A) |
|
Details | ||
| 11/4/2024 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2024 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2024 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 10/25/2024 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/22/2024 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2024 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2024 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/8/2024 | MBX Biosciences Inc | MBX | New Coverage | Overweight (N/A) |
23.75 (43.91) |
84.88% | Details | |
| 10/3/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/19/2024 | Halozyme Therapeutics | HALO | Downgrade | Neutral (Overweight) |
61.93 (68.99) |
11.4% | Details | |
| 9/16/2024 | BioNTech | BNTX | Upgrade | Neutral (Underweight) |
123.40 (90.19) |
-26.91% | Details | |
| 9/13/2024 | Moderna | MRNA | Downgrade | Underweight (Neutral) |
79.51 (59.35) |
-25.36% | Details | |
| 9/5/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/4/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/26/2024 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/26/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 8/21/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/21/2024 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2024 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/19/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2024 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 8/15/2024 | BioNTech | BNTX | Maintain | Underweight (N/A) |
|
Details | ||
| 8/6/2024 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2024 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2024 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 7/29/2024 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2024 | NovoCure Ltd. | NVCR | Maintain | Neutral (N/A) |
|
Details | ||
| 7/25/2024 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 7/23/2024 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 7/19/2024 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2024 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 7/10/2024 | Immunocore Holdings | IMCR | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2024 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 7/9/2024 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/20/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 6/18/2024 | Mirum Pharamceuticals | MIRM | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 6/12/2024 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | BioNTech | BNTX | Maintain | Underweight (N/A) |
|
Details | ||
| 6/6/2024 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2024 | NovoCure Ltd. | NVCR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/28/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/21/2024 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2024 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 4/11/2024 | BeiGene, Ltd. | BGNE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/2/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 3/26/2024 | Stoke Therapeutics | STOK | Maintain | Neutral (N/A) |
|
Details | ||
| 3/25/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 3/22/2024 | BioNTech | BNTX | Maintain | Underweight (N/A) |
|
Details | ||
| 3/20/2024 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/20/2024 | Immunocore Holdings | IMCR | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2024 | Deciphera | DCPH | Maintain | Neutral (N/A) |
|
Details | ||
| 3/19/2024 | NovoCure Ltd. | NVCR | Maintain | Neutral (N/A) |
|
Details | ||
| 3/19/2024 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2024 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2024 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2024 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/29/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 2/6/2024 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/6/2024 | BeiGene, Ltd. | BGNE | New Coverage | Overweight (N/A) |
141.81 (184.71) |
30.25% | Details | |
| 2/1/2024 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/1/2024 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (N/A) |
|
Details | ||
| 1/5/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 1/4/2024 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 12/28/2023 | RayzeBio | RYZB | Downgrade | Neutral (Overweight) |
61.40 (62.49) |
1.78% | Details | |
| 12/28/2023 | Cerevel Therapeutics | CERE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/28/2023 | Karuna Therapeutics Inc. | KRTX | Downgrade | Neutral (Overweight) |
317.00 (329.83) |
4.05% | Details | |
| 12/1/2023 | Moderna | MRNA | Maintain | Underweight (N/A) |
|
Details | ||
| 12/1/2023 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 12/1/2023 | BioNTech | BNTX | Downgrade | Underweight (Neutral) |
99.25 (123.40) |
24.33% | Details | |
| 11/20/2023 | Nektar Therapeutics | NKTR | New Coverage | Underweight (N/A) |
0.50 (65.70) |
13040% | Details | |
| 11/20/2023 | Emergent BioSolutions | EBS | New Coverage | Underweight (N/A) |
2.12 (7.85) |
270.28% | Details | |
| 11/20/2023 | Esperion Therapeutics | ESPR | New Coverage | Neutral (N/A) |
1.11 (3.16) |
184.68% | Details | |
| 11/20/2023 | Stoke Therapeutics | STOK | New Coverage | Neutral (N/A) |
4.17 (30.97) |
642.69% | Details | |
| 11/20/2023 | Amarin Corporation | AMRN | New Coverage | Underweight (N/A) |
0.76 (15.81) |
1980.26% | Details | |
| 11/20/2023 | Deciphera | DCPH | New Coverage | Neutral (N/A) |
12.25 (25.59) |
108.9% | Details | |
| 11/20/2023 | BioCryst Pharma | BCRX | New Coverage | Overweight (N/A) |
5.14 (9.14) |
77.82% | Details | |
| 11/20/2023 | NovoCure Ltd. | NVCR | New Coverage | Neutral (N/A) |
11.83 (13.61) |
15.05% | Details | |
| 11/20/2023 | Mirum Pharamceuticals | MIRM | New Coverage | Overweight (N/A) |
30.31 (107.77) |
255.56% | Details | |
| 11/20/2023 | Immunocore Holdings | IMCR | New Coverage | Overweight (N/A) |
46.89 (29.35) |
-37.41% | Details | |
| 11/20/2023 | Crinetics | CRNX | New Coverage | Overweight (N/A) |
28.34 (35.38) |
24.84% | Details | |
| 11/20/2023 | Denali Therapeutics Inc. | DNLI | New Coverage | Overweight (N/A) |
18.13 (24.05) |
32.65% | Details | |
| 11/20/2023 | Insmed | INSM | New Coverage | Overweight (N/A) |
24.44 (98.61) |
303.48% | Details | |
| 11/20/2023 | Alkermes | ALKS | New Coverage | Neutral (N/A) |
23.37 (46.02) |
96.92% | Details | |
| 11/20/2023 | Cerevel Therapeutics | CERE | New Coverage | Neutral (N/A) |
24.65 (44.96) |
82.39% | Details | |
| 11/2/2023 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2023 | RayzeBio | RYZB | New Coverage | Overweight (N/A) |
20.59 (62.49) |
203.5% | Details | |
| 6/5/2023 | Karuna Therapeutics Inc. | KRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/5/2023 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 5/25/2023 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 5/4/2023 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2023 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 5/2/2023 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2023 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 4/27/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/25/2023 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 4/21/2023 | Stoke Therapeutics | STOK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/21/2023 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 4/21/2023 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/19/2023 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2023 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 4/10/2023 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/10/2023 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 3/17/2023 | Emergent BioSolutions | EBS | Downgrade | Underweight (Neutral) |
9.65 (7.85) |
-18.65% | Details | |
| 3/17/2023 | Cerevel Therapeutics | CERE | Downgrade | Neutral (Overweight) |
24.32 (44.96) |
84.87% | Details | |
| 3/17/2023 | NovoCure Ltd. | NVCR | Downgrade | Underweight (Neutral) |
64.43 (13.61) |
-78.88% | Details | |
| 3/9/2023 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2023 | Cara Therapeutics | CARA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2023 | Esperion Therapeutics | ESPR | Maintain | Neutral (N/A) |
|
Details | ||
| 2/24/2023 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2023 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/22/2023 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/22/2023 | BioCryst Pharma | BCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2023 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 2/16/2023 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2023 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/8/2023 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/8/2023 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/7/2023 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/6/2023 | NovoCure Ltd. | NVCR | Maintain | Neutral (N/A) |
|
Details | ||
| 1/3/2023 | Stoke Therapeutics | STOK | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2023 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 12/22/2022 | NovoCure Ltd. | NVCR | Maintain | Neutral (N/A) |
|
Details | ||
| 12/6/2022 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/22/2022 | Immunocore Holdings | IMCR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/22/2022 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/21/2022 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/21/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/11/2022 | Emergent BioSolutions | EBS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/10/2022 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2022 | Cara Therapeutics | CARA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2022 | Karuna Therapeutics Inc. | KRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2022 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2022 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2022 | Esperion Therapeutics | ESPR | Maintain | Neutral (N/A) |
|
Details | ||
| 10/31/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/26/2022 | Esperion Therapeutics | ESPR | Maintain | Neutral (N/A) |
|
Details | ||
| 10/26/2022 | Emergent BioSolutions | EBS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/25/2022 | Tricida | TCDA | Downgrade | Underweight (Neutral) |
10.88 (0.11) |
-98.99% | Details | |
| 10/24/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2022 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 10/24/2022 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 10/24/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/24/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2022 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2022 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/21/2022 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2022 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2022 | Nektar Therapeutics | NKTR | Downgrade | Underweight (Neutral) |
4.42 (65.70) |
1386.43% | Details | |
| 8/2/2022 | Vertex | VRTX | New Coverage | Overweight (N/A) |
280.41 (466.79) |
66.47% | Details | |
| 8/2/2022 | Seagen | SGEN | New Coverage | Overweight (N/A) |
179.98 (228.74) |
27.09% | Details | |
| 8/2/2022 | NovoCure Ltd. | NVCR | New Coverage | Neutral (N/A) |
67.99 (13.61) |
-79.98% | Details | |
| 8/2/2022 | Moderna | MRNA | New Coverage | Neutral (N/A) |
164.09 (79.51) |
-51.54% | Details | |
| 8/2/2022 | Legand Biotech Corp. | LEGN | New Coverage | Overweight (N/A) |
47.24 (29.34) |
-37.89% | Details | |
| 8/2/2022 | Karuna Therapeutics Inc. | KRTX | New Coverage | Overweight (N/A) |
130.25 (329.83) |
153.23% | Details | |
| 8/2/2022 | Incyte | INCY | New Coverage | Neutral (N/A) |
77.68 (103.66) |
33.44% | Details | |
| 8/2/2022 | Cerevel Therapeutics | CERE | New Coverage | Overweight (N/A) |
26.29 (44.96) |
71.02% | Details | |
| 8/2/2022 | BioNTech | BNTX | New Coverage | Neutral (N/A) |
165.15 (90.19) |
-45.39% | Details | |
| 8/2/2022 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Overweight (N/A) |
86.05 (55.90) |
-35.04% | Details | |
| 8/2/2022 | Alkermes | ALKS | New Coverage | Neutral (N/A) |
25.60 (46.02) |
79.77% | Details | |
| 6/7/2022 | Zymeworks | ZYME | Maintain | Neutral (N/A) |
|
Details | ||
| 6/6/2022 | Amarin Corporation | AMRN | Maintain | Underweight (N/A) |
|
Details | ||
| 5/24/2022 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2022 | Radius Health | RDUS | Maintain | Neutral (N/A) |
|
Details | ||
| 5/6/2022 | Amarin Corporation | AMRN | Downgrade | Underweight (Neutral) |
1.56 (15.81) |
913.46% | Details | |
| 5/5/2022 | Esperion Therapeutics | ESPR | Upgrade | Neutral (Underweight) |
6.53 (3.16) |
-51.61% | Details | |
| 5/2/2022 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 4/20/2022 | Lava Therapeutics NV | LVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/19/2022 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 4/13/2022 | Zymeworks | ZYME | Maintain | Neutral (N/A) |
|
Details | ||
| 3/25/2022 | Radius Health | RDUS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/24/2022 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/14/2022 | Cara Therapeutics | CARA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2022 | Emergent BioSolutions | EBS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/8/2022 | Cara Therapeutics | CARA | Upgrade | Overweight (Neutral) |
10.70 (5.32) |
-50.28% | Details | |
| 3/1/2022 | Nektar Therapeutics | NKTR | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2022 | Rubius | RUBY | Maintain | Neutral (N/A) |
|
Details | ||
| 2/25/2022 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2022 | BioCryst Pharma | BCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2022 | Radius Health | RDUS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/7/2022 | Amarin Corporation | AMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/7/2022 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2022 | Landos Biopharma | LABP | Maintain | Neutral (N/A) |
|
Details | ||
| 11/22/2021 | Stoke Therapeutics | STOK | Upgrade | Overweight (Neutral) |
28.06 (30.97) |
10.37% | Details | |
| 11/16/2021 | Tricida | TCDA | Upgrade | Neutral (Underweight) |
5.46 (0.11) |
-97.99% | Details | |
| 11/12/2021 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/20/2021 | Mirum Pharamceuticals | MIRM | New Coverage | Overweight (N/A) |
18.33 (107.77) |
487.94% | Details | |
| 9/15/2021 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2021 | Aprea | APRE | Downgrade | Underweight (Neutral) |
3.62 (0.79) |
-78.18% | Details | |
| 8/3/2021 | Cara Therapeutics | CARA | New Coverage | Neutral (N/A) |
11.97 (5.32) |
-55.56% | Details | |
| 8/3/2021 | Magenta Therapeutics | MGTA | Downgrade | Neutral (Overweight) |
7.12 (0.70) |
-90.17% | Details | |
| 7/28/2021 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 6/18/2021 | Crinetics | CRNX | Upgrade | Overweight (Overweight) |
18.50 (35.38) |
91.24% | Details | |
| 6/16/2021 | Kaleido Biosciences Inc. | KLDO | Maintain | Underweight (N/A) |
|
Details | ||
| 5/21/2021 | Stoke Therapeutics | STOK | Maintain | (N/A) |
|
Details | ||
| 5/21/2021 | Mersana | MRSN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/21/2021 | Crinetics | CRNX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/19/2021 | Jazz Pharmaceuticals | JAZZ | New Coverage | Overweight (N/A) |
175.09 (225.92) |
29.03% | Details | |
| 4/19/2021 | Lava Therapeutics NV | LVTX | New Coverage | Overweight (N/A) |
15.62 (1.74) |
-88.86% | Details | |
| 3/2/2021 | Immunocore Holdings | IMCR | New Coverage | Overweight (N/A) |
48.36 (29.35) |
-39.31% | Details | |
| 3/1/2021 | Landos Biopharma | LABP | New Coverage | Neutral (N/A) |
12.99 (22.93) |
76.52% | Details | |
| 1/29/2021 | Aptinyx | APTX | Downgrade | Underweight (Neutral) |
3.70 (0.06) |
-98.38% | Details | |
| 1/29/2021 | Lexicon Pharmaceuticals | LXRX | Upgrade | Neutral (Underweight) |
8.06 (2.15) |
-73.33% | Details | |
| 10/14/2020 | Magenta Therapeutics | MGTA | New Coverage | Overweight (N/A) |
7.67 (0.70) |
-90.87% | Details | |
| 10/14/2020 | Crinetics | CRNX | New Coverage | Neutral (N/A) |
16.77 (18.50) |
10.32% | Details | |
| 9/29/2020 | Tricida | TCDA | New Coverage | Underweight (N/A) |
8.87 (0.11) |
-98.76% | Details | |
| 9/29/2020 | Aprea | APRE | New Coverage | Neutral (N/A) |
22.65 (0.79) |
-96.51% | Details | |
| 9/29/2020 | Radius Health | RDUS | New Coverage | Neutral (N/A) |
10.80 (30.00) |
177.78% | Details | |
| 9/29/2020 | BioCryst Pharma | BCRX | New Coverage | Overweight (N/A) |
3.67 (9.14) |
149.05% | Details | |
| 9/29/2020 | Immunogen Inc. | IMGN | New Coverage | Neutral (N/A) |
3.58 (31.25) |
772.91% | Details | |
| 9/29/2020 | Esperion Therapeutics | ESPR | New Coverage | Underweight (N/A) |
37.12 (3.16) |
-91.49% | Details | |
| 9/29/2020 | Stoke Therapeutics | STOK | New Coverage | Neutral (N/A) |
34.93 (30.97) |
-11.34% | Details | |
| 9/29/2020 | Mersana | MRSN | New Coverage | Neutral (N/A) |
19.60 (29.08) |
48.37% | Details | |
| 9/29/2020 | Zymeworks | ZYME | New Coverage | Neutral (N/A) |
44.98 (23.26) |
-48.29% | Details | |
| 9/14/2020 | Deciphera | DCPH | New Coverage | Neutral (N/A) |
44.87 (25.59) |
-42.97% | Details | |
| 9/14/2020 | Nektar Therapeutics | NKTR | New Coverage | Neutral (N/A) |
18.82 (65.70) |
249.1% | Details | |
| 9/14/2020 | Denali Therapeutics Inc. | DNLI | New Coverage | Overweight (N/A) |
31.99 (24.05) |
-24.82% | Details | |
| 9/14/2020 | Arena Pharma | ARNA | New Coverage | Overweight (N/A) |
63.37 (99.98) |
57.77% | Details | |
| 9/14/2020 | Halozyme Therapeutics | HALO | New Coverage | Overweight (N/A) |
27.05 (61.93) |
128.95% | Details | |
| 9/14/2020 | United Therapeutics Corp. | UTHR | New Coverage | Overweight (N/A) |
102.52 (538.30) |
425.07% | Details | |
| 9/14/2020 | Emergent BioSolutions | EBS | New Coverage | Neutral (N/A) |
98.08 (7.85) |
-92% | Details | |
| 9/14/2020 | Ionis Pharmaceuticals | IONS | New Coverage | Neutral (N/A) |
51.97 (69.02) |
32.81% | Details | |
| 9/14/2020 | Ascendis Pharma | ASND | New Coverage | Overweight (N/A) |
144.70 (228.00) |
57.57% | Details | |
| 9/14/2020 | Jazz Pharmaceuticals | JAZZ | New Coverage | Overweight (N/A) |
136.80 (175.09) |
27.99% | Details | |
| 4/6/2020 | Yum! Brands | YUM | Maintain | Neutral (N/A) |
|
Details | ||
| 1/31/2020 | United Therapeutics Corp. | UTHR | Upgrade | Overweight (Neutral) |
96.42 (538.30) |
458.29% | Details | |
| 1/31/2020 | Rubius | RUBY | Downgrade | Neutral (Overweight) |
8.05 (0.08) |
-99.01% | Details | |
| 1/31/2020 | Intra-Cellular Therapies | ITCI | Downgrade | Neutral (Overweight) |
23.54 (131.87) |
460.2% | Details | |
| 1/31/2020 | Arena Pharma | ARNA | Upgrade | Overweight (Neutral) |
44.44 (99.98) |
124.98% | Details | |
| 1/6/2020 | Amarin Corporation | AMRN | New Coverage | Neutral (N/A) |
21.53 (15.81) |
-26.57% | Details | |
| 12/9/2019 | Zymeworks | ZYME | New Coverage | Neutral (N/A) |
41.92 (23.26) |
-44.51% | Details | |
| 10/28/2019 | Aprea | APRE | New Coverage | Neutral (N/A) |
25.70 (0.79) |
-96.93% | Details | |
| 8/13/2019 | Aptinyx | APTX | Downgrade | Underweight (Neutral) |
3.53 (0.06) |
-98.3% | Details | |
| 8/9/2019 | Nektar Therapeutics | NKTR | Downgrade | Neutral (Overweight) |
29.57 (65.70) |
122.18% | Details | |
| 3/25/2019 | Kaleido Biosciences Inc. | KLDO | New Coverage | Neutral (N/A) |
13.52 (0.00) |
-100% | Details | |
| 3/19/2019 | Yum! Brands | YUM | Downgrade | Neutral (Overweight) |
100.90 (150.74) |
49.4% | Details | |
| 3/19/2019 | Immunogen Inc. | IMGN | Downgrade | Underweight (Neutral) |
2.65 (31.25) |
1079.25% | Details | |
| 3/13/2019 | Esperion Therapeutics | ESPR | Upgrade | Neutral (Underweight) |
49.81 (3.16) |
-93.66% | Details | |
| 3/11/2019 | Mersana | MRSN | Downgrade | Underweight (Neutral) |
4.22 (29.08) |
589.1% | Details | |
| 1/17/2019 | Aptinyx | APTX | Downgrade | Neutral (Overweight) |
17.83 (3.53) |
-80.2% | Details | |
| 12/11/2018 | Stemline Therapeutics | STML | New Coverage | Overweight (N/A) |
9.98 (11.83) |
18.54% | Details | |
| 11/6/2018 | AMAG Pharmaceuticals | AMAG | Downgrade | Underweight (Neutral) |
18.29 (13.75) |
-24.82% | Details | |
| 8/13/2018 | Crinetics | CRNX | New Coverage | Neutral (N/A) |
29.84 (35.38) |
18.57% | Details | |
| 8/13/2018 | Rubius | RUBY | New Coverage | Overweight (N/A) |
21.93 (0.08) |
-99.64% | Details |
